According to Choice data, as of January 3, a total of 88 listed companies had released performance forecasts for 2022, of which 61 listed companies had "expected" performance (including turning losses, slightly increasing, continuing gains and expected increases), accounting for 69.32%. Kweichow Moutai is expected to have a net profit of 62.6 billion yuan. The reporter combed the performance forecast and noticed that as of January 3, there were 16 listed companies whose net profits in 2022 were expected to grow by 100% or more. For example, Shanghai Yizhong's announcement shows that the company is expected to achieve a net profit of 150 million yuan to 160 million yuan in 2022, compared with a loss in the same period last year. Referring to the reasons why the company is expected to turn losses into profits, Shanghai Yizhong said that the commercial production and sales of paclitaxel polymer micelles for injection, the core product of the company, had been officially carried out after it was approved for listing at the end of 2021; In addition, Gaochi Shares is expected to make a profit of 760 million yuan to 820 million yuan in 2022, with an increase of 340.09% to 374.83%. As for the reasons for the growth of performance, Gaoshi Shares said that in 2022, thanks to the steady progress of the "dual carbon" goal, the market demand of the photovoltaic industry will continue to be strong, the company's products will remain in the leading position in the industry, product competitiveness will continue to improve, equipment orders will increase significantly, and the operating income and net profit of photovoltaic cutting equipment will achieve a significant increase compared with last year. From the perspective of net profit, Kweichow Moutai is expected to have the highest net profit so far. According to the company's announcement, Kweichow Moutai is expected to achieve a net profit attributable to shareholders of listed companies of 62.6 billion yuan in 2022, up 19.33% year on year; In addition, Guanghui Energy is expected to make a profit of 11.3 billion yuan to 11.5 billion yuan in 2022, with a year-on-year growth of 125.86% to 129.86%; And Lucent Precision expects to achieve a net profit of 9.545 billion yuan to 9.899 billion yuan in 2022, up 35% to 40% year on year. Brilliant performance in the biomedical and battery industries According to the disclosed 2022 performance forecast, the performance of the biomedical and battery industries was outstanding. As of January 3, a total of 9 biopharmaceutical companies have issued performance forecasts, of which only one company's performance is expected to decrease, while the other 8 companies' performance is expected to develop well, and the net profit growth of 4 listed companies is expected to be more than 100%. Specifically, Jardine Realm, whose main products are household non-invasive ventilators, respirators and sleep monitors, is expected to achieve a net profit of 351 million yuan to 407 million yuan in 2022, up 140.85% to 179.67% year on year; In addition, it is estimated that the net profit of Chuanning Biotech will increase by 243% to 269% in 2022, with an estimated profit of 382 million yuan to 411 million yuan; Shanwaishan is expected to make a profit of 42.39 million yuan to 63.58 million yuan in 2022, with a growth rate of 117.68% to 226.5%,. As for the performance growth of the pharmaceutical and biological industry, Deng Zhidong, the general manager of Hainan Boao Medical Technology Co., Ltd., said in an interview with the Securities Daily: "The biomedical industry continues to increase investment in research and development, constantly achieve technological breakthroughs, and accelerate international travel, which has improved the profitability of enterprises." In addition to the biomedical industry, the performance of listed companies in the battery industry is also worth mentioning